Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
News and updates for Travere Therapeutics, Inc. (TVTX) center on its work as a biopharmaceutical company focused on rare kidney, liver and metabolic diseases. Company announcements frequently highlight progress with FILSPARI (sparsentan), an oral, non-immunosuppressive therapy approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN), and under supplemental FDA review as a potential treatment for focal segmental glomerulosclerosis (FSGS).
Investors following TVTX news can track regulatory milestones such as FDA review timelines, PDUFA target action dates and review extensions for the FILSPARI sNDA in FSGS. Travere also reports new clinical data from the Phase 3 DUPLEX and Phase 2 DUET studies in FSGS, as well as from PROTECT, SPARTAN and real-world analyses in IgAN. These updates often focus on proteinuria reduction, kidney function outcomes and correlations between biomarker changes and long-term kidney failure risk.
Travere’s news flow includes financial results and preliminary revenue updates, typically furnished via press releases and Form 8‑K filings, along with commentary on commercial performance of FILSPARI in IgAN. The company also issues releases on pipeline developments, including the planned restart of the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) and long-term metabolite reduction data from the COMPOSE study.
Additional news items cover partnership activities with CSL Vifor and Renalys Pharma, anticipated regional filings and launches, and Travere’s participation in major medical and investor conferences such as the American Society of Nephrology Kidney Week and large healthcare investment meetings. This page aggregates these developments so readers can follow how clinical, regulatory, commercial and partnership events may shape the company’s rare disease portfolio over time.
Travere Therapeutics (Nasdaq: TVTX) has announced a voluntary pause in enrollment for its Phase 3 HARMONY Study of pegtibatinase, a potential treatment for classical homocystinuria (HCU). This decision was made to address necessary process improvements in manufacturing scale-up for commercial production. Currently enrolled patients will continue to receive study medication from unaffected small-scale batches.
The pause was initiated after the company determined that the desired drug substance profile was not achieved in the recent scale-up process. Travere expects to restart enrollment in the HARMONY Study no earlier than 2026. As a result, the company anticipates a reduction in research and development expenses by more than $30 million in 2025 compared to 2024. Travere's cash reserves of $325.4 million as of June 30, 2024, are expected to support operations into 2028.
Travere Therapeutics (NASDAQ: TVTX) announced that on September 10, 2024, its Compensation Committee granted inducement equity grants to six new employees. These grants consist of restricted stock units (RSUs) covering a total of 33,500 shares of common stock. The RSUs were granted outside of Travere's 2018 Equity Incentive Plan but are subject to its terms. They were provided as inducements for new employees joining Travere, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs have a four-year vesting schedule, with 25% of the shares vesting annually on the grant date anniversary, contingent on the employee's continued service with Travere.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will present on Tuesday, September 17, 2024, at 9:45 a.m. ET. This event provides an opportunity for investors and interested parties to gain insights into Travere's latest developments and strategies.
A live webcast of the presentation will be available on the Investor page of Travere's website at ir.travere.com/events-presentations. For those unable to attend the live event, a replay will be accessible for up to 30 days following the conference. This allows stakeholders to stay informed about Travere's progress and future plans in the healthcare sector.
Ligand Pharmaceuticals (Nasdaq: LGND) announced that its partner Travere Therapeutics received full FDA approval for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. This approval is based on positive long-term results from the PROTECT Study, showing FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.
Key points:
- FILSPARI is the only non-immunosuppressive treatment for IgAN
- Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI
- FILSPARI demonstrated superior long-term kidney function preservation compared to irbesartan
- The FDA-approved label includes two-year efficacy data
Ligand's CEO, Todd Davis, expressed optimism about FILSPARI's potential as a significant revenue driver for the company in the coming years.
Travere Therapeutics announced FDA full approval of FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. FILSPARI is the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN. The approval is based on positive long-term results from the PROTECT Study, showing superior kidney function preservation compared to irbesartan over two years.
Key points:
- FILSPARI is an oral, once-daily medication that targets glomerular injury in the kidney
- It demonstrated a statistically significant treatment effect of 1.2 mL/min/1.73 m2/year in eGFR slope
- The drug showed durable benefits on proteinuria and was well-tolerated
- FILSPARI has the potential to become foundational care in IgAN
Travere Therapeutics (Nasdaq: TVTX) will present two posters on classical homocystinuria (HCU) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Porto, Portugal, September 3-6, 2024. The presentations will focus on the trial designs of:
- The pivotal Phase 3 HARMONY Study
- ENSEMBLE long-term extension study
- Cohort 7 in the Phase 1/2 COMPOSE Study
All studies involve pegtibatinase, a novel investigational enzyme replacement therapy for HCU. Travere believes pegtibatinase could become the first disease-modifying therapy for classical HCU by effectively replacing the deficient CBS enzyme activity. The posters will be presented on September 4, 2024, from 6:15 – 8:15 p.m. GMT+1 at the Rosa Mota Pavilion.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two upcoming investor conferences in August 2024. The company will present at the 2024 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, at 2:30 p.m. ET, and the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, at 12:30 p.m. ET.
A live webcast of the Canaccord Genuity conference presentation will be available on Travere's website investor page, with a replay accessible for up to 30 days after the event. This announcement highlights Travere's commitment to engaging with investors and sharing company updates through these important industry events.
Travere Therapeutics (NASDAQ: TVTX) reported strong Q2 2024 financial results, highlighting the success of FILSPARI® (sparsentan) in treating IgAN. Key points include:
- 521 new patient start forms (PSFs) for FILSPARI, totaling 2,484 since launch
- FILSPARI net product sales of $27.1 million, up 37% from previous quarter
- Total revenue of $54.1 million, including $52.2 million in net product sales
- Cash position of $325.4 million as of June 30, 2024
The company is preparing for the September 5, 2024 PDUFA date for full approval of FILSPARI in IgAN. Travere is also advancing global expansion efforts and progressing its pegtibatinase Phase 3 program for classical homocystinuria.
Travere Therapeutics (NASDAQ: TVTX) has announced that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. Investors can access the webcast and dial-in information on Travere's website at ir.travere.com/events-presentations. An archived version of the call will be available for 30 days on the company's website following the live webcast.
Travere Therapeutics (NASDAQ: TVTX) will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on July 15, 2024, at 11:30 a.m. ET. The presentation will be accessible via live webcast on the company's Investor page, and a replay will be available for 30 days post-event. The company's management will discuss key developments and insights related to their kidney disease therapeutics pipeline.